The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System
Abstract
Cognitive impairments during psychotic episodes are assumed to be caused not only by one single putative classical neurotransmitter dysfunction but also by an impaired equilibrium of the interaction between different neurobiological generators of cognitive processes. Herein, the perceptual abnormalities induced by psychotogenic agents play a major role as tools for the understanding of model psychoses. The recently discovered cannabinoid receptor system with its endogenous ligand anandamide can be regarded as an extremely relevant regulator system, a dysfunctionality of which may explain at least one subtype of endogenous psychoses. Neuropsychological results (three-dimensional inversion illusion) in delta 9-tetrahydrocannabinol-intoxicated normal volunteers exhibit strong similarities with data acquired from patients suffering from productive schizophrenic psychoses, regarding disturbances in internal regulation of perceptual processes. The relevance of this finding to a general cognitive dysfunction concept of schizophrenic psychosis is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“other studies have suggested that the induction of “pro-psychotic” states in non-clinical populations, via, for example, acute cannabinoids (Emrich et al., 1997; Leweke et al., 1999; Koethe et al., 2006), chronic intoxication (Semple et al., 2003) or sleep deprivation (Sternemann et al., 1997), enable to experimentally reduce sensitivity to VIs.”
From What visual illusions teach us about schizophrenia (2014) · cites this paper as Emrich et al., 1997
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,389
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,862
Dopamine receptor pharmacology
Seeman, P. M., & Tol, H. H. M. V. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90323-9 · Cited by 969
BONE-MARROW TRANSPLANTATION IN A PATIENT WITH THE WISKOTT-ALDRICH SYNDROME
Bach, F. H., Albertini, R., Joo, P., Anderson, J., & Bortin, M. M. (1968) · The Lancet · doi:10.1016/s0140-6736(68)92672-x · Cited by 867
Hollister, L. E. (1987) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(87)90030-4 · Cited by 500
Significance and meaning of neurological signs in schizophrenia
Heinrichs, D. W., & Buchanan, R. W. (1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.1.11 · Cited by 433
Research works printed but not linked: 1
- Schröder, 1993, Diskrete motorische und sensorische Störungen (neurologische soft signs) im Akutverlauf endogener Psychosen, Z. Klin. Psychol. Psychopathol. Psychother., 41, 190
Cited by
Sorted by citations
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Iversen, L. L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 751
Metadata
- Authors
- Emrich, H. M., Leweke, F. M., & Schneider, U.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Emrich, Hinderk M
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 1997-04
- Volume
- 56
- Issue
- 4
- Pages
- 803-807
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W1986173065
- Cited by
- 226
- References
- 35
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 16 · 2017: 7 · 2016: 8 · 2015: 5 · 2014: 8 · 2013: 3 · 2012: 8
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacology Biochemistry and Behavior (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- schizophrenia, endocannabinoid system, anandamide, cognitive impairment, perceptual disorders, cannabinoid receptors, psychosis
- MeSH terms
- Adult, Cannabinoids, Depth Perception, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Receptors, Drug, Schizophrenia, Schizophrenic Psychology, Vision, Binocular, Receptors, Cannabinoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
